Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel thiazole derivative or salt, isomer, preparation method and application thereof

A technology of tautomers and stereoisomers, which is applied in the therapeutic field to achieve the effects of fast absorption, low clearance rate and long half-life

Active Publication Date: 2021-02-09
CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Opioid abuse is a major public health problem in the U.S. because of its pain-relieving effects; 78 people die from opioid overdose every day

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel thiazole derivative or salt, isomer, preparation method and application thereof
  • Novel thiazole derivative or salt, isomer, preparation method and application thereof
  • Novel thiazole derivative or salt, isomer, preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1: Preparation of 4-{2-{[5-(naphthalene-2-yl)thiazol-2-yl]oxy}ethyl}morpholine

[0060]

[0061] Step 1, at room temperature, compound IIa (2.43g, 10mmol), compound VI (1.97g, 15mmol), Cs 2 CO 3 (9.75g, 30mmol) was added into DMF (30mL), heated to 100°C, reacted for 6h, and the raw materials were completely reacted. The reaction solution was cooled to room temperature, and H 2 O (30mL), extracted three times with ethyl acetate (50mL*3), the organic phase was washed with water and saturated brine successively, the organic phase was dried with anhydrous sodium sulfate, filtered, the filtrate was spin-dried, and the crude product was used as eluent petroleum ether: Ethyl acetate=3:1 was passed through the column, spin-dried, and vacuum-dried to obtain 2.50 g of the product. Yield: 85.2%.

[0062] Step 2, at room temperature, compound Va (2.50g, 8.5mmol), compound naphthalene-2-ylboronic acid (1.76g, 10.2mmol), CsF (1.55g, 10.2mmol) were added to 1,4-dioxane / ...

Embodiment 2

[0065] Example 2: Preparation of 4-{2-{[5-phenylthiazol-2-yl]oxy}ethyl}morpholine

[0066]

[0067] According to the preparation method of Example 1, the 2-naphthylboronic acid in step 2 was replaced by an equimolar amount of phenylboronic acid to obtain the title compound with a yield of 80.4% and a purity of 99.46%.

[0068] ESI-MS:m / z=291.2(M+H) + .

[0069] 1 H NMR (400MHz, CDCl 3 )δ7.46–7.42(m,2H),7.39–7.34(m,2H),7.31–7.27(m,2H),4.57(t,J=5.6Hz,2H),3.76–3.73(m,4H) , 2.83 (t, J=5.6Hz, 2H), 2.61–2.54 (m, 4H).

Embodiment 3

[0070] Example 3: Preparation of 4-{2-{[5-(3,4-dichlorophenyl)thiazol-2-yl]oxy}ethyl}morpholine

[0071]

[0072] According to the preparation method of Example 1, the 2-naphthylboronic acid in step 2 was replaced by an equimolar amount of 3,4-dichlorophenylboronic acid to obtain the title compound with a yield of 82.5% and a purity of 99.77%.

[0073] ESI-MS:m / z=359.2(M+H) + .

[0074] 1 H NMR (400MHz, CDCl 3 )δ7.51(d, J=2.1Hz, 1H), 7.42(d, J=8.4Hz, 1H), 7.30(s, 1H), 7.24(d, J=2.1Hz, 1H), 4.58(t, J=5.6Hz, 2H), 3.76–3.72(m, 4H), 2.82(t, J=5.6Hz, 2H), 2.61–2.53(m, 4H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a novel thiazole derivative or salt, an isomer, a preparation method and application thereof. A compound shown as a formula (I) has a Sigma 1 receptor antagonism effect, and has strong in vitro affinity to sigma 1R in the aspect of in vitro receptor affinity. Meanwhile, in D2L radioactive ligand binding analysis and 5HT-1A receptor, CB1 receptor and CB2 receptor cAMP tests,the affinity to the receptors is poor, and high receptor selectivity is shown. Mouse acetic acid twisting tests show that the compound has an analgesic effect. Through rat oral administration pharmacokinetic experiments, it can be known that the compound is long in half-life period, low in clearance rate and large in AUClast; Cmax can be quickly reached after oral administration, and the compoundis extremely quick to absorb and suitable for medicine.

Description

technical field [0001] The present invention relates to the field of medicinal chemistry, in particular to thiazole derivatives or their salts, isomers, their preparation method and the application of their pharmaceutical composition in the preparation of treatment and prevention, especially in pain, drug addiction, opioid drug synergism , psychosis, etc. in the treatment of purposes. Background technique [0002] At present, the incidence rate of pain in the world is about 35-45%, and the incidence rate of the elderly is even higher, about 75%-90%. Pain is the third therapeutic field in the world, and the market is huge. Opioids are currently the most powerful and commonly used central analgesics. Past studies have shown that opioids (such as codeine, morphine, oxycodone, and fentanyl) can effectively relieve pain. They bind to opioid receptors in the brain, spinal cord, and gastrointestinal tract to relieve pain. Precisely because of their remarkable pain-relieving effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D277/34C07D417/04A61P1/12A61P25/06A61P3/04A61P3/06A61P19/02A61P29/00A61P9/12A61P9/06A61P25/28A61P25/30A61P25/24A61P25/18A61P35/00A61P1/04A61P9/00A61P25/04A61K31/5377
CPCC07D277/34C07D417/04A61P1/12A61P25/06A61P3/04A61P3/06A61P19/02A61P29/00A61P9/12A61P9/06A61P25/28A61P25/30A61P25/24A61P25/18A61P35/00A61P1/04A61P9/00A61P25/04
Inventor 曾燕群鄢胜勇马云龙张涛王颖
Owner CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com